Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology

Symptoms and Progression of AIDP

At a Glance

AIDP symptoms typically progress in an ascending pattern, starting with tingling and weakness in the feet and moving upward. Most patients reach their peak weakness, known as the nadir, within four weeks. Severe progression can affect breathing and heart rate, requiring close medical monitoring.

The progression of Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) can feel like a race against time, but there is a classic pattern that doctors look for to manage your care effectively. Understanding these symptoms can help you and your caregivers communicate more clearly with your medical team.

The Classic Pattern: Ascending Paralysis

The hallmark of AIDP is symmetric weakness, meaning it usually affects both sides of the body equally [1][2].

  • Starting Point: Symptoms often begin with tingling (“pins and needles”) or numbness in the toes and fingertips [3].
  • The “Ascending” Path: The weakness typically moves from the feet upward to the legs, then the torso, and finally the arms and face [4].
  • Areflexia: Early in the process, doctors will notice a loss of deep tendon reflexes (areflexia) [1]. This means when they tap your knee or ankle with a medical hammer, there is little to no involuntary movement [2].
  • Pain: Many patients (up to 50-89%) experience significant nerve or muscle pain, often described as a deep ache in the back or legs, which can occur even before the weakness is fully realized [1][5].

Reaching the “Nadir”

The term nadir refers to the point where the symptoms are at their absolute worst [6].

  • Timeline: About 80-90% of patients reach their nadir within four weeks [6][7].
  • Significance: Once you have stayed at this “low point” without getting worse for a few days, it is a sign that the immune attack has likely stopped, and the recovery phase can eventually begin [8].

Monitoring for Severe Risks

Because AIDP affects the nerves that control your muscles, it can also affect the muscles you don’t think about, like those used for breathing and heart regulation.

1. Respiratory Insufficiency

About 20-30% of GBS patients will require a ventilator to help them breathe during the peak of the illness [9]. Doctors watch for bulbar weakness—weakness in the muscles of the throat and face—as a major warning sign [10][11].

  • Warning Signs: Difficulty swallowing, a “nasal” or hoarse voice, trouble clearing phlegm, or being unable to finish a sentence in one breath [12][13].

2. Autonomic Dysfunction

The autonomic nervous system controls involuntary functions like heart rate and blood pressure. When these nerves are affected, it is called autonomic dysfunction [14][15].

  • Heart and Blood Pressure: You may experience a racing heart (tachycardia), irregular rhythms, or blood pressure that swings from very high to very low [14][16].
  • Digestion and Bladder: This can also cause urinary retention (difficulty peeing) or severe constipation [15].

Summary of Symptom Progression

Phase Typical Timing Primary Symptoms
Early Days 1–7 Tingling in toes/fingers, leg weakness, loss of reflexes [3][1].
Progressive Days 7–28 Weakness moving up the body, potential pain, difficulty walking [4][6].
Critical Variable Potential difficulty breathing, swallowing issues, or heart rate changes [10][14].
Nadir By Week 4 Maximum weakness reached; condition stabilizes [6][7].

Your care team will use tools like the Erasmus GBS Respiratory Insufficiency Score (EGRIS) to predict if you might need extra breathing support, ensuring they are ready to help before a crisis occurs [17][18].

(Return to the Home Page)

Common questions in this guide

What is the classic pattern of AIDP weakness?
Weakness in AIDP typically follows an ascending pattern. It usually begins with tingling and numbness in the toes and fingers, then progressively moves upward into the legs, torso, arms, and face.
What does reaching the nadir mean in AIDP?
The nadir is the point where your AIDP symptoms are at their absolute worst. Most patients reach this low point within four weeks. Once your symptoms stop worsening and stabilize for a few days, it indicates the immune attack has likely paused and recovery can eventually begin.
Why do doctors monitor my breathing if AIDP primarily affects my arms and legs?
AIDP can progress to affect the nerves that control your involuntary muscles, including your diaphragm and throat. Up to 30 percent of patients may temporarily need a ventilator, so doctors closely monitor breathing to provide support before it becomes an emergency.
Can AIDP cause heart or blood pressure problems?
Yes, AIDP can interfere with the autonomic nervous system, which controls automatic bodily functions. This can lead to a racing heart, irregular heart rhythms, and drastic swings in your blood pressure.
Is pain a common symptom of AIDP?
Yes, more than half of patients experience significant nerve or muscle pain. This is frequently described as a deep, severe ache in the back or legs, and it can occur even before the muscle weakness becomes obvious.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my current muscle strength score (MRC sum score) being tracked to monitor my progression?
  2. 2.How frequently are we doing bedside breathing tests to watch for respiratory issues?
  3. 3.What specific signs of autonomic dysfunction, like heart rate or blood pressure changes, are you monitoring for?
  4. 4.If my swallowing becomes difficult (bulbar weakness), what is the plan for my nutrition and safety?
  5. 5.Do my reflexes show 'areflexia,' and how does that help confirm the AIDP diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Headache and Pain in Guillain-Barré Syndrome.

    Farmakidis C, Inan S, Milstein M, Herskovitz S

    Current pain and headache reports 2015; (19(8)):40 doi:10.1007/s11916-015-0508-x.

    PMID: 26122532
  2. 2

    Complication of Hepatitis A Infection: Case Report of Acute Inflammatory Demyelinating Polyneuropathy.

    Laursen D, Krug J, Wolford R

    Clinical practice and cases in emergency medicine 2021; (5(1)):113-116 doi:10.5811/cpcem.2020.9.48827.

    PMID: 33560967
  3. 3

    [Target Molecule for a Demyelinating Type of Guillain-Barré Syndrome, Acute Inflammatory Demyelinating Polyneuropathy].

    Mori M

    Brain and nerve = Shinkei kenkyu no shinpo 2015; (67(11)):1359-69 doi:10.11477/mf.1416200306.

    PMID: 26560951
  4. 4

    Clinical Features Indicating the Need for Mechanical Ventilation in Patients with Guillain Barre Syndrome.

    Umer SR, Nisa Q, Kumari M, et al.

    Cureus 2019; (11(8)):e5520 doi:10.7759/cureus.5520.

    PMID: 31687295
  5. 5

    Pain in acute motor axonal neuropathy.

    Zhao F, Wang J, Zhang J, et al.

    Muscle & nerve 2021; (64(6)):739-743 doi:10.1002/mus.27414.

    PMID: 34506042
  6. 6

    Clinical features and outcome of Guillain-Barre syndrome in Saudi Arabia: a multicenter, retrospective study.

    Alanazy MH, Bakry SS, Alqahtani A, et al.

    BMC neurology 2021; (21(1)):275 doi:10.1186/s12883-021-02314-5.

    PMID: 34253174
  7. 7

    Differentiating Familial Neuropathies from Guillain-Barré Syndrome.

    Bordini BJ, Monrad P

    Pediatric clinics of North America 2017; (64(1)):231-252 doi:10.1016/j.pcl.2016.08.015.

    PMID: 27894447
  8. 8

    Rate of progression of Guillain-Barré syndrome is not associated with the short-term outcome of the disease.

    Arsenijević M, Berisavac I, Mladenović B, et al.

    Irish journal of medical science 2021; (190(1)):357-361 doi:10.1007/s11845-020-02310-7.

    PMID: 32666503
  9. 9

    International Validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score.

    Doets AY, Walgaard C, Lingsma HF, et al.

    Annals of neurology 2022; (91(4)):521-531 doi:10.1002/ana.26312.

    PMID: 35106830
  10. 10

    Clinical study of the relationship between hepatitis B core antibody and mechanical ventilation in patients with Guillain-Barré syndrome.

    Zhang W, Yao Q, Wang Y, et al.

    Frontiers in neurology 2025; (16()):1530286 doi:10.3389/fneur.2025.1530286.

    PMID: 40066308
  11. 11

    Factors Associated with Respiratory Insufficiency in Children with Guillain-Barré Syndrome.

    Sun RD, Jiang J, Deng XL

    Neuropediatrics 2024; (55(2)):112-116 doi:10.1055/s-0043-1777767.

    PMID: 38253279
  12. 12

    Clinical predictors and electrodiagnostic characteristics in patients with Guillain-Barré syndrome with respiratory failure: a retrospective, matched case-control study.

    Charoentanyarak K, Singjam A, Saengsuwan J

    PeerJ 2022; (10()):e12930 doi:10.7717/peerj.12930.

    PMID: 35186497
  13. 13

    Risk factors of disease severity and mechanical ventilation requirement in childhood Guillain-Barré Syndrome.

    Yücel G, Arslan AK, Özgör B, Güngör S

    The Turkish journal of pediatrics 2024; (66(6)):746-757 doi:10.24953/turkjpediatr.2024.4658.

    PMID: 39807741
  14. 14

    Guillain-Barre Syndrome in Children and Adolescents.

    Langille MM

    Advances in pediatrics 2023; (70(1)):91-103 doi:10.1016/j.yapd.2023.04.001.

    PMID: 37422300
  15. 15

    Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China.

    Zhang G, Li Q, Zhang R, et al.

    PloS one 2015; (10(7)):e0133520 doi:10.1371/journal.pone.0133520.

    PMID: 26200903
  16. 16

    Guillain-Barré syndrome complicated by takotsubo cardiomyopathy: an under-recognised association.

    Jones T, Umaskanth N, De Boisanger J, Penn H

    BMJ case reports 2020; (13(2)) doi:10.1136/bcr-2019-233591.

    PMID: 32060115
  17. 17

    Clinico-epidemiological profile and prediction of outcome in children with Guillain-Barre syndrome.

    Priyadarshini D, Anuhya V, Mahapatra A

    Italian journal of pediatrics 2025; (51(1)):179 doi:10.1186/s13052-025-02037-0.

    PMID: 40483522
  18. 18

    Risk Factors for Mechanical Ventilation in Patients with Guillain-Barré Syndrome.

    Cheng Y, Liu K, Li C, et al.

    Neurocritical care 2022; (37(1)):121-128 doi:10.1007/s12028-022-01457-8.

    PMID: 35338435

This page provides educational information about the symptoms and progression of AIDP. It does not replace professional medical evaluation; seek immediate emergency care if you experience difficulty breathing, swallowing, or sudden weakness.

Get notified when new evidence is published on Acute inflammatory demyelinating polyradiculoneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.